Tri-Institutional MD-PhD Program, Weill Medical College and Graduate School of Medical Sciences of Cornell University, New York, New York, United States of America.
PLoS One. 2012;7(6):e39769. doi: 10.1371/journal.pone.0039769. Epub 2012 Jun 26.
The most severe form of human malaria is caused by the parasite Plasmodium falciparum. The second messenger cAMP has been shown to be important for the parasite's ability to infect the host's liver, but its role during parasite growth inside erythrocytes, the stage responsible for symptomatic malaria, is less clear. The P. falciparum genome encodes two adenylyl cyclases, the enzymes that synthesize cAMP, PfACα and PfACβ. We now show that one of these, PfACβ, plays an important role during the erythrocytic stage of the P. falciparum life cycle. Biochemical characterization of PfACβ revealed a marked pH dependence, and sensitivity to a number of small molecule inhibitors. These inhibitors kill parasites growing inside red blood cells. One particular inhibitor is selective for PfACβ relative to its human ortholog, soluble adenylyl cyclase (sAC); thus, PfACβ represents a potential target for development of safe and effective antimalarial therapeutics.
最严重的人类疟疾是由疟原虫引起的。第二信使 cAMP 已被证明对寄生虫感染宿主肝脏的能力很重要,但在寄生虫在红细胞内生长(导致疟疾症状的阶段)期间,其作用不太清楚。疟原虫基因组编码两种腺苷酸环化酶,即合成 cAMP 的酶,PfACα 和 PfACβ。我们现在表明,其中一种,PfACβ,在疟原虫生命周期的红细胞阶段发挥重要作用。PfACβ 的生化特性表明其对 pH 值有明显的依赖性,并对许多小分子抑制剂敏感。这些抑制剂可杀死在红细胞内生长的寄生虫。一种特殊的抑制剂对 PfACβ 相对于其人类同源物可溶性腺苷酸环化酶(sAC)具有选择性;因此,PfACβ 代表了开发安全有效的抗疟治疗药物的潜在目标。